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Crim1 has cell-autonomous and 
paracrine roles during embryonic 
heart development
Swati Iyer1, Fang Yu Chou1, Richard Wang1, Han Sheng Chiu1, Vinay K. Sundar Raju1, 
Melissa H. Little2,3,4, Walter G. Thomas1, Michael Piper1,5 & David J. Pennisi1
The epicardium has a critical role during embryonic development, contributing epicardium-derived 
lineages to the heart, as well as providing regulatory and trophic signals necessary for myocardial 
development. Crim1 is a unique trans-membrane protein expressed by epicardial and epicardially-
derived cells but its role in cardiogenesis is unknown. Using knockout mouse models, we observe that 
loss of Crim1 leads to congenital heart defects including epicardial defects and hypoplastic ventricular 
compact myocardium. Epicardium-restricted deletion of Crim1 results in increased epithelial-to-
mesenchymal transition and invasion of the myocardium in vivo, and an increased migration of primary 
epicardial cells. Furthermore, Crim1 appears to be necessary for the proliferation of epicardium-
derived cells (EPDCs) and for their subsequent differentiation into cardiac fibroblasts. It is also required 
for normal levels of cardiomyocyte proliferation and apoptosis, consistent with a role in regulating 
epicardium-derived trophic factors that act on the myocardium. Mechanistically, Crim1 may also 
modulate key developmentally expressed growth factors such as TGFβs, as changes in the downstream 
effectors phospho-SMAD2 and phospho-ERK1/2 are observed in the absence of Crim1. Collectively, 
our data demonstrates that Crim1 is essential for cell-autonomous and paracrine aspects of heart 
development.
During development, the heart is invested with cells of the proepicardium (PE), a structure that will give rise to 
the epicardium, myocardial fibroblasts, cells of the coronary vasculature and some cells of the valves1–4. A critical 
step in the formation of these epicardium-derived lineages is the epithelial-to-mesenchymal transition (EMT) 
that epicardial cells must undergo to occupy the sub-epicardial space or to invade the myocardium. Some fac-
tors implicated in promoting epicardial EMT and invasion include FGFs, PDGF-A/B, TGFβ -1/2/3, and BMP-2 
5–8, while these processes are restrained by NF19 and WT110. However, the molecular factors that control epi-
cardial EMT and myocardial invasion, and the differentiation of epicardium-derived lineages, are incompletely 
understood.
Crim1 is a type-I transmembrane protein that is broadly expressed during development and which has been 
shown to regulate embryonic development of multiple organ systems11–14. We have previously demonstrated 
embryonic lethality in mice homozygous for the Crim1KST264 genetrap and Crim1Δflox null alleles11,15, and that 
homozygous Crim1KST264/KST264 mice display defects in organ systems including the kidney, limb, eye and placenta. 
These mice die perinatally on a C57BL6 background11. The Crim1Δflox/Δflox mice display similar defects but there 
exist variations in severity and penetrance of the phenotypes, likely due to differences in the type of mutation 
used to generate each mouse line15. The Crim1Δflox homozygotes are also embryonic lethal on the C57BL6 back-
ground15. The underlying role of this molecule in vivo is complex, and likely involves interactions with growth 
factors and the extracellular milieu. Crim1 is homologous to the BMP-regulating protein Chordin, and contains 
six von Willebrand factor, type C-like cysteine-rich repeats (CRRs) through which it binds a broad range growth 
factors including TGFβ , BMP, VEGF and PDGF, when Crim1 is co-expressed in the same cell as the growth fac-
tor12,13. Moreover, Crim1 can variably have an agonistic or antagonistic effect on BMP signaling13,16,17, although 
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this activity may be context-dependent. In the heart, it is expressed in PE-derived lineages, including the epicar-
dium, and coronary vasculature11, however, its role in cardiogenesis, along with the growth factors it interacts 
with at different stages, is unclear.
In this study, we demonstrate essential autocrine and paracrine roles for Crim1 in heart development. Crim1 
loss-of-function and genetrap mice display congenital heart defects such as ventricular septal defects, epicardial 
defects and hypoplastic ventricular myocardium. We reveal an involvement of Crim1 in regulating epicardial 
cell migration into the myocardium both in vivo and in vitro. Crim1 also limits EMT in a manner independent 
of canonical TGFβ signaling, but possibly via an interaction with β -catenin, a crucial component of adherens 
junctions, which has been previously shown to complex indirectly with Crim118. Interestingly, the cells that have 
lost Crim1 and have taken up residence in the myocardium, proliferate less, and give rise to a reduced number of 
cardiac fibroblasts, suggesting a further cell-autonomous role for Crim1 in fate specification of cells derived from 
the epicardium. We also provide evidence that upon loss of Crim1 function, compact myocardial development is 
aberrant, likely due to epicardial loss of Crim1, indicative of a paracrine role. Collectively, these findings illustrate 
how Crim1 and other factors function in tandem to regulate heart development.
Results
Expression of Crim1 during heart development using a genetrap reporter. To investigate Crim1 
expression in the developing heart, we used a genetrap line for Crim1, Crim1KST264 11 that allowed the use of a 
LacZ reporter under the control of the Crim1 locus. We observed Crim1 expression in the proepicardium at 
9.5 days post coitum (dpc), and in the epicardium at all stages during cardiac development (Fig. 1A–M). Crim1 
was also expressed in coronary vascular smooth muscle and coronary endothelial cells, as reported previously11. 
Crim1 expression in the endocardium and valve leaflets was confirmed by performing X-Gal staining coupled 
with immunohistochemical analyses against periostin, a mesenchymal cell marker (Supplementary Fig. 1A–E), 
and Crim1 expression in coronary vascular smooth muscle cells was confirmed using transgelin double labelling 
(Supplementary Fig. 1F). The dynamic expression pattern observed suggests that Crim1 plays a role in heart 
development.
Developmental defects in hearts of Crim1 mutant embryos. The expression pattern of Crim1 led 
us to investigate whether there were heart defects exhibited by Crim1 mutant mice. Examination of hearts from 
embryos homozygous for the Crim1KST264 genetrap mutant (Supplementary Fig. 2A–L) revealed epicardial malfor-
mations and blebbing (Supplementary Fig. 2J–L), as well as a reduced ventricular size (Supplementary Fig. 2A–C) 
and muscular ventricular septal defects (Supplementary Fig. 2D–I). Similarly, Crim1Δflox/Δflox embryonic hearts 
had reduced ventricle size at 14.5 dpc (Fig. 2A,B,D,E), and distended atria and reduced ventricular size at 17.0 dpc 
(Fig. 2C,F). Histological analysis of Crim1Δflox/Δflox hearts at 13.5 dpc revealed abnormal epicardial morphology, 
including epicardial blistering (Fig. 2G–I,N), findings supported by scanning electron microscopic analysis of 
Crim1Δflox/Δflox hearts, which revealed a loss of the regular, cobblestone appearance of the epicardium (Fig. 2J–M).
These phenotypes may have arisen from deficits in early PE formation. To address this, we used in situ hybrid-
ization on Crim1Δflox/Δflox embryos for the PE markers Gata4 and Tbx18. We found that PE formation and mor-
phology, and PE marker expression, was similar between Crim1Δflox/Δflox and control embryos (Supplementary 
Fig. 3), indicating that Crim1 is not necessary for initial outgrowth of the PE. From this we infer that Crim1 may 
regulate adhesion or migration at a later time point within the developing epicardium.
Crim1 is necessary for normal compact myocardial development. As we had observed a reduction 
in ventricular size at 14.5 dpc in Crim1Δflox/Δflox hearts, we investigated whether there were any changes in thick-
ness of the compact myocardium at 13.0 dpc (when the myocardium has started to develop) that could underlie 
this phenotype. We observed a reduced compact myocardial thickness in Crim1Δflox/Δflox hearts at 13.0 dpc, a 
finding that was not due to changes in cell density (Fig. 3A–D). Interestingly, this phenotype is shared by other 
mutants that lack epicardium or epicardium-derived factors19. To further examine the nature of this defect, we 
analyzed the proliferation marker, phospho-histone H3 (pHH3; Fig. 3E–F), and the apoptotic marker, cleaved 
caspase 3 (CC3; Fig. 3I–J). We found an almost two-fold increase in proliferation, and a four-fold increase in 
apoptosis in the compact myocardium of Crim1Δflox/Δflox hearts (Fig. 3H,L). No change was observed in prolifera-
tion or apoptosis in epicardial or sub-epicardial cells of Crim1Δflox/Δflox hearts at this age (Fig. 3G,K). This suggests 
that the loss of Crim1 culminates in elevated cell death within the compact myocardium during development, but 
whether it is an autocrine effect of Crim1 expressed within the compact myocardium, or epicardially-expressed 
Crim1 acting in a paracrine manner, is unknown.
To address this question, we analyzed the potential autocrine role of Crim1 in compact myocardial develop-
ment by deleting Crim1 from the cardiomyocytes in the myocardium of the developing heart using the Mlc2v-Cre 
line. This line is efficient and restricted to ventricular cardiomyocytes20–23. Cardiomyocyte proliferation and 
survival upon myocardial loss of Crim1 in the ventricular myocardium were examined using pHH3 and CC3 
immunocytochemistry, respectively. Quantification of cells expressing both X-Gal and pHH3, or cells expressing 
X-Gal and CC3 in the compact myocardium at 13.5 dpc revealed no significant differences in the number of either 
pHH3- and CC3-positive cells between control and mutant hearts (Supplementary Fig. 4). Moreover, no signif-
icant change in compact myocardium thickness was observed in these mice (Supplementary Fig. 4). From this, 
and the fact that the compact myocardium phenotype is observed before the epicardial cells have undergone EMT 
and invaded the compact myocardium, we infer that the myocardial deletion of Crim1 does not give rise to defi-
cits in the compact myocardium, but rather that epicardial Crim1 regulates the development of the myocardium 
in a paracrine fashion. In order to substantiate this, we crossed the conditional Crim1FLOX line to a strain that 
would enable inducible ablation of Crim1 from the epicardium (WT1-CreERT2). The WT1-CreERT2 line has pre-
viously been shown to be specific to the epicardium and epicardium-derived lineages24. We further corroborated 
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Figure 1. Crim1 expression as monitored by the Crim1KST264 genetrap reporter reveals a dynamic pattern 
during heart development. (A) micrograph of a histological section of a 9.5 dpc Crim1+/KST264 embryo that has 
been X-Gal-stained, paraffin-embedded, and counter-stained with nuclear fast red. (B) higher magnification 
view of the boxed area in (A). The proepicardial cells are X-Gal-positive (arrow, B). Note that X-Gal staining 
is localised close to nuclei due to the targeting of the β -geo to cell bodies that was typical of the secretory trap 
vector used in the genetrap screen that generated the Crim1KST264 allele [49]. (C–G) Whole-mount views of 
Crim1+/KST264 hearts after X-Gal staining (blue) at 12.5 dpc (C), 15.5 dpc (D), 16.5 dpc (E), 17.5 dpc (F), and 
18.5 dpc (G). In addition to expression in the epicardium at these stages, note the Crim1-LacZ expression  
-in the OFT mesenchyme (arrows) at 12.5 dpc, and the smooth muscle of the great vessels (arrows, D–G).  
(H–J) Magnified left lateral views of the ventricles of the hearts shown in (E–G) respectively. Note the 
www.nature.com/scientificreports/
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this by immunohistochemical analysis using the cardiomyocyte marker MF20, which revealed limited overlap 
between the X-Gal staining and MF20 immunoreactivity (Supplementary Fig. 5D,E). Two doses of Tamoxifen 
were administered at 9.5 dpc and 10.5 dpc prior to harvesting the embryos, and epicardial-restricted Cre activity 
as assessed by the R26R LacZ reporter was confirmed in embryonic hearts from 12.5 dpc (Fig. 4F,G,J,K, and data 
not shown). Unlike the hearts of Crim1Δflox/Δflox mice, the phenotype of reduced myocardial wall thickness was 
not recapitulated in the WT1-CreERT2 hearts at 15.5 dpc (data not shown). This could be due to incomplete 
penetrance and variable expressivity; a common occurrence with Cre lines, including the WT1-CreERT2 line24. 
Indeed, upon quantification of the percentage of epicardial cells that had lost Crim1 (pooled genotypes, n = 6; 
data not shown), we saw that in the left and right ventricles, there were still 62.5% of epicardial cells in which 
Crim1 was not ablated, which could compensate for any myocardial defects that may have arisen with a complete 
lack of Crim1.
Cell-autonomous requirement for Crim1 to control epicardial migration and myocardial inva-
sion in vitro and in vivo. Given the potential role for epicardially-derived Crim1 in regulating myocardial 
development, as well as the epicardial defects observed in the hearts of conditional null and genetrap mutant 
embryos, we next examined the role of Crim1 in epicardial development. We first sought to determine whether 
Crim1 mutant epicardial cells exhibited migration defects. To do this we cultured primary embryonic epicardial 
cells from the Crim1KST264 genetrap line in a transwell migration assay (modified Boyden chamber assay). The 
Crim1KST264 allele in these experiments allowed us to monitor the continued expression of Crim1 by X-Gal stain-
ing in representative examples of explant cultures. In all cases, ubiquitous Crim1-LacZ expression was observed 
in primary epicardial cells (data not shown). We found that primary epicardial cultures from Crim1KST264/KST264 
hearts, immunostained with WT1 as an epicardial marker to confirm epicardial identity after enrichment 
(Fig. 4D), exhibited an increased rate of migration relative to heterozygote controls (Fig. 4A–E), suggesting that 
the loss of Crim1 from the developing epicardium resulted in increased epicardial migration.
To confirm these observations in vivo, and to also investigate changes in EMT, we used the WT1-CreERT2 
line and assessed the location of X-Gal-positive cells at 15.5 dpc in Crim1FLOX/FLOX; WT1-CreERT2; R26R and lit-
termate heterozygous controls, determining whether labelled cells remained epicardial, or had undergone EMT 
and migrated to the sub-epicardium or to an intramural myocardial location. We found that loss of Crim1 in 
epicardial cells resulted in an increase in the number of epicardial cells that had undergone EMT and invaded the 
myocardium of the right ventricle relative to controls (Fig. 4F–M). This finding was confirmed using a second Cre 
driver, namely WT1-Cre25 (data not shown). These in vivo data indicate that the loss of Crim1 in the epicardium 
results in increased epicardial EMT, and are consistent with the primary epicardial culture migration experiments 
indicating that the loss of Crim1 function results in increased epicardial cell migration.
To gain insight into the mechanism by which Crim1 may regulate EMT and the migration of epicardial cells, 
we next investigated whether growth factor signalling in both the epicardium and the myocardium is perturbed 
in Crim1-deficient mice. Numerous growth factors have been implicated in epicardial EMT, including TGFβ 
and BMPs (acting via TGFβ receptors)5–8. As Crim1 has been shown to bind such growth factors in cell culture 
binding experiments12,13,26, and potentially regulate their activity in vivo12,26, we examined whether there were 
changes in canonical TGFβ or BMP signalling at the time of epicardial EMT and invasion, using the Crim1Δflox 
line. To do this we performed indirect immunofluorescence for phospho-SMAD2 and phospho-SMAD1/5 as 
proxies to assess canonical TGFβ and BMP signalling, respectively. We also investigated whether there were 
changes in downstream effectors such as ERK1/2 and AKT as further read-outs of aberrant signal transduc-
tion. There was a reduced level of phospho-SMAD2 in the epicardium of Crim1Δflox/Δflox hearts at 13.0 dpc (77% 
and 69% of control values for the left and right ventricular epicardium, respectively) (Fig. 5A–F). Despite the 
increased epicardial EMT and invasion suggested by the epicardial-restricted loss of Crim1 function, these results 
suggest that canonical TGFβ signalling was reduced in the epicardium of Crim1Δflox/Δflox hearts. There was no 
change in levels of phospho-SMAD1/5 (Supplementary Fig. 6A–H), phospho-AKT (Supplementary Fig. 6I–P) 
and phospho-ERK1/2 (Fig. 5I–N) in the epicardium of Crim1Δflox/Δflox hearts relative to wildtype controls. At 
13.0 dpc, Crim1Δflox/Δflox hearts showed comparable levels of ventricular compact myocardial phospho-SMAD2 
(Fig. 5A,B,E–H), phospho-SMAD1/5 (Supplementary Fig. 6A–H) and phospho-AKT (Supplementary Fig. 6I–P) 
relative to controls. However, we observed that there was an increase in both the number of phospho-ERK1/2 
positive cells (for example, 29% of cells were phospho-Erk1/2-positive in the left ventricle of the mutant, com-
pared to 6% in the left ventricle of the control; P < 0.05, t-test), as well as an increase in the phospho-ERK1/2 sig-
nal intensity per cell in the ventricular compact myocardium of mutant hearts relative to controls (Fig. 5I,J,M–P). 
There was also no significant difference in the distance that pERK1/2 positive cells were from the epicardium 
in both control and mutant hearts (data not shown). Together with the lack of compact myocardial changes 
observed in the myocardium-restricted Crim1 knock-out, this indicates that Crim1 could play a paracrine role in 
regulating myocardial development, likely through the regulation of epicardium-derived factors.
The adhesion molecule β -catenin is an important regulator of epithelial stability and EMT, and Crim1 
has been shown to interact indirectly with β -catenin18. To investigate the role of Crim1 in altering EMT and 
migration, we analyzed the localisation of β -catenin27 in Crim1+/+ and Crim1Δflox/Δflox hearts at 13.5 dpc. We 
found that there was a decrease in the percentage of epicardial cells that displayed an accumulation of β -catenin 
Crim1-LacZ expression in the developing coronary vasculature (arrows) and in the epicardium (double open 
arrowheads). (K–M) histological sections Crim1-LacZ expression in the epicardium (arrows) and (M) in the 
coronary vasculature (open arrowhead). my, myocardium; pe, proepicardium. Scale bar (A) 100 μ m; (B) 20 μ m; 
(C) 200 μ m; (D–G) 500 μ m; (H–J) 200 μ m; (K–M) 20 μ m.
www.nature.com/scientificreports/
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Figure 2. Developmental defects in hearts of Crim1Δflox/Δflox embryos. (A,B,D,E) Representative whole-
mount views of 14.5 dpc embryonic hearts (A,B, Crim1+/+; D,E Crim1Δflox/Δflox). (B,E) Magnified, left lateral 
views of (A,D) respectively. (C,F) Representative whole-mount views of 17 dpc embryonic hearts (C, Crim1+/+; 
(F) Crim1Δflox/Δflox). Note the reduced size of the ventricles in the Crim1Δflox/Δflox heart (D–F). Epicardial defects 
in Crim1Δflox/Δflox hearts. (G–I) Hematoxylin and eosin-stained sections of the ventricular region of 13.5 dpc 
(G) Crim1+/+ and (H,I) two different Crim1Δflox/Δflox hearts. Note the irregular appearance of the epicardium 
www.nature.com/scientificreports/
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at epicardial cell-cell junctions in mutant hearts (Fig. 5Q–W). When considered in light of the findings that 
increased EMT and myocardial invasion occurs in the hearts of Crim1 mutant mice, this finding suggests that 
Crim1 normally regulates the stability of intercellular junctions within the epicardium. Analysis of filamentous 
actin to assess the cytoskeletal remodelling that accompanies EMT and migration revealed no visible changes in 
stress fibre morphology between mutant and wildtype hearts at 13.5 dpc (Supplementary Fig. 7). The data reveal 
a cell-autonomous role for Crim1 in controlling epicardial migration, EMT and invasion in primary cell culture 
and in vivo, which appears to rely on interactions with β -catenin.
Cell-autonomous requirement for Crim1 to control proliferation and fate specification of 
EPDCs. The increase in the number of EPDCs that had migrated into the myocardium prompted us to further 
investigate the proliferative ability and differentiation potential of these EPDCs. We used the WT1-CreERT2 and 
Crim1FLOX; R26R lines and assessed EPDC proliferation at 15.5 dpc using pHH3 (Fig. 6A,B). Quantification of 
X-Gal expressing cells that were pHH3-positive in the myocardium of left and right ventricles revealed a sig-
nificant reduction in proliferation of intramyocardial cells in Crim1FLOX/FLOX; + /WT1-CreERT2; R26R hearts 
(Fig. 6D). Quantification of pHH3-positive cells among X-Gal-positive epicardial cells, however, revealed com-
parable results (Fig. 6C). This demonstrates that deleting Crim1 from the epicardium can perturb proliferation of 
epicardium-derived cells, even though there is increased migration into the myocardium.
To address whether changes in epicardial cell fate occurred due to loss of Crim1, we performed qPCR analyses 
on ventricular tissue from 17.5 dpc Crim1Δflox/Δflox and Crim1+/+ hearts using vascular smooth muscle, fibro-
blast and cardiomyocyte markers. No significant changes in these markers were observed, although there was 
a trend for a reduction in the fibroblast marker Collagen1a (P = 0.0556; Supplementary Fig. 8A). To specifi-
cally examine the effect of epicardial Crim1 deletion on the differentiation of EPDCs into cardiac fibroblasts, 
we used the WT1-CreERT2 line to perform IHC using periostin, another fibroblast marker, on heterozygote 
control and mutant WT1-CreERT2 heart sections at 17.5 dpc. Quantification of the proportion of periostin- and 
X-Gal-positive cells in the myocardium revealed a significant decrease in the expression of periostin in the left 
and right ventricles of the mutant (Fig. 6E–I). This suggests that the number of cardiac fibroblasts were reduced, 
and the secretory phenotype of cardiac fibroblasts was perturbed upon epicardial Crim1 loss-of-function, indi-
cating a possible cell-autonomous requirement for Crim1 to regulate fate specification of EPDCs into fibroblasts.
Discussion
The epicardium gives rise to crucial components of the developing heart, and while the differentiation of EPDCs 
into cardiomyocytes and coronary endothelial cells remains a controversial topic, reactivated epicardial cells after 
myocardial damage have been shown to give rise to fibroblast and smooth muscle cells28–32. The epicardium also 
has a critical role in providing instructive cues and trophic factors for the developing myocardium. Although cer-
tain epicardium-derived factors are believed to act on the myocardium in a paracrine manner, the nature of this 
interaction is not entirely understood. Here, we demonstrate an essential role for Crim1 in the epicardium during 
heart development. Crim1 appears to regulate epicardial EMT and invasion, fate specification of EPDCs into 
cardiac fibroblasts, and modulation of growth factor activity. As a result, we infer that Crim1 controls compact 
myocardial development via regulation of epicardium-derived paracrine factors.
Crim1 is expressed in a large number of tissues in a spatially and temporally regulated manner and has been 
shown to have diverse extracellular and intracellular functions11–14,18,33,34. This study focused determining the role 
of Crim1 in the cardiogenesis by using different transgenic mouse lines. We have observed that Crim1 expression 
in the heart begins in the proepicardium, although it is not necessary for PE specification, and continues in 
the epicardium and epicardium-derived lineages. Crim1KST264/KST264 homozygotes showed a disrupted epicardial 
layer, reduced ventricular size, and prominent ventricular septal defects. Hearts of both Crim1Δflox/Δflox and 
Crim1KST264/KST264 homozygotes at 13.5 dpc showed irregular epicardial morphology indicative of EMT and 
adhesion defects. Indeed, epicardial deletion of Crim1 resulted in an increase in epicardial cell EMT and 
myocardial invasion. Similarly, primary epicardial cultures showed increased migration upon loss of Crim1. 
However, epicardial cells lacking Crim1 also showed reduced proliferation and an overall reduction in cardiac 
fibroblast marker expression. Overall this suggests that loss of Crim1 in epicardial cells affects cell phenotype, 
proliferation and fate.
Growth factors like BMPs and TGFβ s that can be bound by Crim1 promote epicardial EMT and invasion5,7,8. 
Canonical BMP signalling via the SMAD1/5 pathway, AKT signalling and ERK1/2 in the epicardium appear to be 
largely independent of Crim1 in Crim1Δflox/Δflox hearts. Indeed, we observed a paradoxical reduction in epicardial 
TGFβ signalling in Crim1Δflox/Δflox embryos. This suggests that, in the epicardium, Crim1 may play a role other 
than growth factor regulation with Crim1 mutants representing an uncoupling of these growth factor signalling 
pathways and epicardial EMT. β -catenin distribution, however, at epicardial cell-cell junctions was altered in 
the absence of Crim1. Interestingly, Xenopus Crim1 has been shown to interact via its cytoplasmic domain with 
β -catenin and N-cadherin, identifying a role for Crim1 in the formation or stabilization of cadherin-dependent 
junctional complexes in epithelial cells18. Though Crim1 was not always present at sites of cadherin expression, 
in Crim1Δflox/Δflox embryos, with one example showing blebbing (H). (J–M) Scanning electron micrographs 
of the ventricular surface of 13.5 dpc Crim1+/+ (J,L) and Crim1Δflox/Δflox (K,M) hearts. (K) Note the loss of the 
even spacing of cells of the mesothelial epicardium, and (M) diffusely arranged microvilli. (N) Quantification 
of penetrance of epicardial defects, specifically either epicardial blebbing or a loss of squamous morphology, 
between Crim1+/+ and Crim1Δflox/Δflox hearts at 13.5 dpc. Z-score -3.8801. *P < 0.0001. cm, compact 
myocardium; ep, epicardium. Scale bars; A–F, 500 μ m; G-I, 50 μ m; J-K, 20 μ m; L-M, 2 μ m.
www.nature.com/scientificreports/
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it may interact with cadherins and β -catenin within the endoplasmic reticulum, where complex formation 
between the 3 interacting partners would occur, possibly displacing an existing stabilization mechanism18. 
Crim1-mediated sequestration of β -catenin from junctional complexes could also limit Wnt signalling. Hence, 
the link between Crim1 and the β -catenin pathway, particularly in the developmental interactions between the 
epicardium and myocardium, remains to be explored.
The altered myocardial thickness in the absence of Crim1 suggests a role for Crim1 in the regulation of sig-
nalling molecules from the epicardium, and possibly the myocardium as well, crucial for normal myocardial 
development. The underlying mechanism that controls the developing myocardium is not clear. Mouse mutants, 
including knockouts of VCAM-1, α 4 integrin and WT-1, and mouse lines with altered retinoic acid signal-
ling, show perturbation of epicardial formation with secondary myocardial defects during development35–38. 
Furthermore, microsurgical inhibition of epicardium formation in avian embryos results in hypoplastic ventricu-
lar compact myocardium39,40. Similarly, we observed a reduced compact myocardial thickness in Crim1Δflox/Δflox 
hearts at 13.0 dpc. However, epicardium-specific deletion of Crim1 did not recapitulate this phenotype, possibly 
due to incomplete penetrance within the WT1-CreERT2 line during embryonic stages. Similarly, the myocardial 
depletion of Crim1 did not culminate in a thinner myocardium, nor did it reveal an effect on cardiomyocyte 
proliferation or apoptosis. In light of the fact that reciprocal signalling between the epicardium and myocar-
dium is required for proper myocardial development to ensue, it is plausible that both epicardial and myocardial 
Crim1 are required for normal formation of the myocardium. An alternative interpretation of these results is that 
there is a non-cell-autonomous requirement for epicardial Crim1 in myocardial development. Embryonic car-
diomyocytes respond to a variety of signalling molecules and express a broad range of receptors which can bind 
mitogenic factors19. Indeed, IGFs, PDGFs and VEGFs secreted by the epicardium may act as epicardial mitogens 
that stimulate ventricular development and cardiomyocyte proliferation41,42. IGFBPs are known to regulate the 
Figure 3. Crim1 is necessary for normal compact myocardial development. (A,B) Merged confocal images 
of left ventricular sections of 13.0 dpc hearts from Crim1+/+ (A) and Crim1Δflox/Δflox (B) hearts stained with 
DAPI (blue), PECAM-1 (red), and actin (green). (C) Compact myocardium cell density was unchanged 
in Crim1Δflox/Δflox hearts. (D) Reduced ventricular compact myocardial thickness in Crim1Δflox/Δflox hearts 
at 13.0 dpc (n = 6–8). (E,F) Merged confocal images of ventricular sections of 13.0 dpc hearts stained with 
phospho- Histone H3 (pHH3, white), DAPI (blue), and actin (green). An epicardial cell (arrowhead, E) and 
myocardial cell (arrowhead, F) immuno-positive for pHH3 are shown. (G) No difference in proliferation 
in the epicardium of Crim1Δflox/Δflox hearts. (H) An almost two-fold increase in proliferation in the compact 
myocardium of Crim1Δflox/Δflox hearts. (I,J) Examples of merged confocal images of ventricular sections of 
13.0 dpc hearts stained with cleaved caspase 3 (CC3, white), DAPI (blue), and actin (green). An epicardial cell 
(arrowhead, I) and myocardial cell (arrowhead, J) immuno-positive for CC3 are shown. (K) No difference 
in apoptosis in the epicardium of Crim1Δflox/Δflox hearts. (H) A four-fold increase in apoptosis in the compact 
myocardium of Crim1Δflox/Δflox hearts. cm, compact myocardium; ep, epicardium; n.s., not significant. (n = 4–5), 
*P < 0.05; **P < 0.01. Scale bars (A,B) 50 μ m; (E,F,I,J) 20 μ m.
www.nature.com/scientificreports/
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activity of IGFs43. The IGFBP domain of Crim1 has been shown to possess sequence similarity to IGFBP-714 
potentially allowing it to bind IGFs and insulin to mediate the regulation of their downstream signalling. This is in 
accordance with our observation that ERK1/2 signalling in the myocardium of Crim1Δflox/Δflox hearts is increased. 
Crim1 may serve to sequester growth factors secreted by the epicardium, without necessarily affecting the range 
of growth factor action in Crim1Δflox/Δflox hearts, where these may be free to signal to the adjacent myocardium. 
This has been reported previously with respect to a role for Crim1 in VEGF sequestration in the glomerulus12. 
Crim1 and the growth factors it binds have been reported to be co-expressed in the same cell12,13, which would 
be consistent with a role in tethering epicardially-derived growth factors. Prolonged ERK1/2 phosphorylation 
has been shown to lead to cell death, whereas transient activation drives proliferation44. Thus, an increase in 
phospho-ERK1/2 activity in the compact myocardium could have a pro- or anti-apoptotic effect, depending on 
the activation of downstream effectors. Crim1 has also been shown to reduce the production and secretion of 
BMPs13. A lack of Crim1 could lead to increased growth factor production and signalling, and result in a high 
cell turnover in the myocardium of mutant hearts as a result of co-activation of proliferation and apoptosis. It is 
important to note that the antagonistic or agonistic functions of Crim1 are context-dependent and could change 
for different cell types within the heart and at different stages of development.
We also observed a decrease in the proliferative ability of EPDCs in the myocardium of Crim1FLOX/FLOX; 
WT1-CreERT2; R26R hearts, in spite of an increased migration of cells derived from the epicardium as seen 
in the Crim1FLOX/FLOX; WT1-CreERT2; R26R and Crim1FLOX/FLOX; WT1-Cre; R26R hearts. This was observed 
alongside a reduction in the number of cardiac fibroblasts, one of the major derivatives of the epicardium1,3,45. 
Figure 4. A cell-autonomous requirement for Crim1 to control epicardial migration and myocardial 
invasion in vitro and in vivo. (A) Schematic of the transwell assay used for the in vitro migration assay. 
(B) Representative micrograph of a primary 11.5 dpc ventricular explant after attachment and migration of 
epicardial cells. The front of the epicardial monolayer is indicated (arrows). The primary explant is denoted 
by an asterisk. (C) Primary epicardial cells after removal of the ventricular explant, passage and subsequent 
culture. Note maintenance of a “cobblestone” appearance of the cellular monolayer. (D) Epicardial identity 
after enrichment was confirmed by immunostaining for WT1 (green nuclear signal). The no-primary antibody 
control showed no signal (inset). (E) Crim1KST264/KST264 primary epicardial cells showed increased migration  
in vitro relative to controls (n = 3–5 and representative of three independent experiments; *P < 0.05).  
(F,J) Whole-mount dorsal views of 15.5 dpc embryonic hearts after X-Gal staining (blue) of Crim1+/FLOX; WT1-
CreERT2; R26R and Crim1FLOX/FLOX; WT1-CreERT2; R26R genotype, respectively. Two doses of Tamoxifen were 
administered at 9.5 dpc and 10.5 dpc prior to harvesting the embryos. (G,K) Histological sections of hearts from 
Crim1+/FLOX; WT1-CreERT2; R26R and Crim1FLOX/FLOX; WT1-CreERT2; R26R 15.5 dpc embryos, respectively, 
and (H,L) magnified views of boxed regions showing X-Gal-positive epicardial, sub-epicardial and intramural 
cells. (I,M) Quantification of X-Gal-positive cells showing increased myocardial EPDCs in the right ventricles 
of mutant hearts (n = 4–6; *P < 0.05). ep, epicardial; se, sub-epicardial; my, intramyocardial; LV, left ventricle; 
RV, right ventricle. Scale bars, (G,K) 20 μ m (H,L) 10 μ m.
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Figure 5. Changes in epicardial and myocardial signalling, alongside localisation of β-catenin in 
Crim1Δflox/Δflox hearts. (A,B,E,F), Confocal images of ventricular sections of 13.0 dpc hearts from Crim1+/Δflox 
(A,B) and Crim1Δflox/Δflox (E,F) embryos stained for phospho-SMAD2/3 (white). (A,B) merged images of 
DAPI (blue) and actin (green) to delineate the myocardium with the phospho-SMAD2/3 (white) from B and F, 
respectively. (C,D,G,H) There was a reduction in phospho-SMAD2 signal intensity in epicardial cells of left  
and right ventricles of Crim1Δflox/Δflox hearts, but the levels in compact myocardial cells was unchanged 
(n = 4–5). Confocal images of ventricular sections of 13.5 dpc hearts from Crim1+/+ (I,J) and Crim1Δflox/Δflox 
(M,N) embryos stained for phospho-ERK1/2 (red). (I,M) merged images of DAPI (blue) and phospho-ERK1/2 
(red). (K,L,O,P), There was an increase in phospho-ERK1/2 signal intensity in compact myocardial cells of  
left and right ventricles of Crim1Δflox/Δflox hearts, but the levels in epicardial cells was unchanged (n = 8–6).  
(Q,R,T,U) Confocal images of ventricular sections of 13.5 dpc hearts from Crim1+/+ (Q,R,S) and Crim1Δflox/Δflox 
(T,U,V) embryos stained for β -catenin (red). (Q,T) merged images of DAPI (blue) and MF20 (green) to 
delineate the epicardium with the β -catenin (red) from (R,S,U,V) respectively. (S,V) magnified views of boxed 
regions in (R,U). Note β -catenin distribution at epicardial cell-cell junctions of Crim1+/+ hearts (arrows, R,S),  
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Cardiac fibroblasts represent a crucial component of the myocardium, secreting a large number of ECM mole-
cules required to support other resident cells of the heart, as well as growth factors and cytokines for the proper 
functioning of these cells46. However, there is little known about the factors that contribute to cardiac fibroblast 
fate specification. These EPDCs that have lost Crim1 could remain undifferentiated cells residing in the com-
pact myocardium, or preferentially ‘switch’ to coronary vascular smooth muscle cells rather than cardiac fibro-
blasts. Cardiac fibroblasts generated after injury are crucial to cardiac repair in terms of both the ECM molecules 
secreted as well as overall cardiac performance29,47. Our data indicate a cell-autonomous requirement for Crim1 
in the production of cardiac fibroblasts. Further studies are required to validate the role of Crim1 in lineage 
specification into fibroblasts and to also address whether it plays a cell-autonomous role in the differentiation of 
EPDCs into coronary vascular smooth muscle cells.
In summary, this study reveals a role for epicardial Crim1 in normal heart development. Although thought 
to be a largely quiescent lining surrounding the myocardium, there has been significant recent focus on ways 
to reactivate the adult epicardium in response to injury and disease48. This revolves around re-expression of 
embryonic epicardial genes and the release of paracrine and autocrine factors from the epicardium or EPDCs48. 
An active participant in epicardially-regulated heart development, Crim1 modulation may therefore provide a 
potential avenue for future molecular and cellular therapeutic interventions in cardiac regeneration and repair. 
Moreover, whether or not abnormal CRIM1 expression plays a role in congenital human heart disease will be an 
important topic for future investigations.
Methods
Ethics statement. The work performed in this study conformed to The University of Queensland’s Animal 
Welfare Unit guidelines for animal use in research, and followed the National Institutes of Health Guide for the 
Care and Use of Animals and the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes. All experimental protocols were approved by The University of Queensland’s Animal Ethics Unit 
(Animal Ethics Committee approval numbers: AIBN/274/08/NHMRC, SMBS/420/11/NHMRC).
Animal breeding. The mouse lines used in this study were the Crim1FLOX conditional mutant15, Crim1Δflox 
knock-out15 and Crim1KST264 genetrap line11, ROSA26 Cre-reporter line (R26R)49, WT1-Cre line25, WT1-CreERT2 
line24,50 and Mlc2v-Cre line20. The Crim1KST264 mouse line was created as part of a genetrap screen51, with insertion 
of the β -Geo cassette into intron 1 of Crim1 resulting in the fusion of exon 1 and the β -Geo cassette within the 
Crim1 transcript, thereby creating a hypomorphic allele which expresses a minor, alternately spliced isoform of 
CRIM111. The Crim1FLOX conditional mutant mouse line was generated, using Cre/LoxP recombination, by flank-
ing exons 3 and 4 with unidirectional LoxP sites15. These Crim1FLOX mice were crossed with a line that expressed 
Cre recombinase ubiquitously (CMV-Cre) to produce the Crim1Δflox line. This deletion created an out-of-frame 
transcript and a predicted non-functional protein and as such, Crim1 is deleted from all tissues in these mice15. 
All lines were maintained on a C57Bl6 genetic background. Embryos were obtained from timed matings between 
Crim1+/Δflox intercrosses, Crim1+/KST264 intercrosses, or Crim1FLOX/FLOX; R26R females mated with Crim1+/FLOX; 
WT1-Cre, Crim1+/FLOX; + /WT1-CreERT2 or Crim1+/FLOX; Mlc2v-Cre males.
Sample preparation. Mouse embryos were obtained from timed matings between Crim1+/Δflox inter-
crosses or Crim1+/KST264 intercrosses, with the presence of a vaginal plug regarded as 0.5 days post coitum (dpc). 
Embryonic hearts were dissected in PBS and fixed for 2 hours in 4% PFA/PBS at 4 °C, washed in PBS, and photo-
graphed in whole-mount. Samples were then dehydrated and processed for paraffin infusion and embedding, and 
7 μ m sections were cut on a microtome. Hematoxylin and eosin staining was performed using standard protocols. 
Embryonic hearts collected from matings between Crim1+/Δflox intercrosses collected at E13.0 and E13.5 were 
also fixed in 4% PFA/PBS at 4 °C, washed in PBS, cryo-protected in 30% sucrose/PBS at 4 °C, embedded in OCT 
(Tissue-Tek) and 10 μ m sections were cut on a cryostat and air-dried before proceeding with the immunofluo-
rescence procedure.
Timed matings were set up between Crim1+/FLOX; WT1-Cre males and Crim1FLOX/FLOX; R26R females to pro-
duce Crim1+/FLOX; WT1-Cre; R26R and Crim1FLOX/FLOX; WT1-Cre; R26R embryos collected at 15.5 dpc (at this 
stage, the myocardium has expanded and cells derived from the epicardium have started to differentiate into 
various lineages), Crim1+/FLOX; + /WT1-CreERT2 males and Crim1FLOX/FLOX; R26R females, for the production of 
Crim1+/FLOX; + /WT1-CreERT2; R26R and CrimFLOX/FLOX; + /WT1-CreERT2; R26R embryos collected at 15.5 dpc 
and 17.5 dpc (at 17.5 dpc, cells derived from the epicardium have differentiated into cardiac fibroblasts, coro-
nary vascular smooth muscle cells, and a small proportion of coronary vascular endothelial cells), and between 
Crim1+/FLOX; Mlc2v-Cre males and Crim1FLOX/FLOX; R26R females to produce Crim1+/FLOX; Mlc2v-Cre; R26R and 
Crim1FLOX/FLOX; Mlc2v-Cre; R26R embryos collected at 13.5 dpc (the myocardium has begun to expand at this 
stage through proliferation of cardiomyocytes).
Embryonic samples from the WT1-Cre, WT1-CreERT2 and Mlc2v-Cre (β -galactosidase activity being 
a readout of Cre activity based on the R26R reporter) and Crim1+/KST264 intercrosses (β -galactosidase activity 
being under the control of the endogenous Crim1 promoter) were X-Gal-stained in whole-mount as previously 
described6 before processing for paraffin embedding and sectioning as described above. Some X-Gal-stained 
and a decreased accumulation at epicardial cell junctions in mutants (double arrowheads, V). (W) the 
percentage of epicardial cells with an accumulation of β -catenin at cell junctions (n = 5–6). cm, compact 
myocardium; ep, epicardium; s.ep, sub epicardium. n.s., not significant. *P < 0.05. Scale bars, (A,B,E,F) 10 μ m 
(I,J,M,N) 50 μ m (Q,R,T,U) 10 μ m.
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Figure 6. Epicardium-restricted Crim1 loss-of-function results in decreased proliferation of EPDCs  
and cardiac fibroblasts in both left and right ventricles. (A,B) phospho-Histone H3 immunohistochemistry 
on X-Gal stained Crim1+/FLOX; + /WT1-CreERT2; R26R and Crim1FLOX/FLOX; + /WT1-CreERT2; R26R sections  
at 15.5 dpc, counter stained with 1% DAB followed by NFR staining for visualisation of nuclei, showing  
(A) pHH3- and X-Gal-positive nuclei (arrow) and (B), a pHH3-positive nucleus (open arrowhead).  
(C,D) Quantification of proliferating EPDCs showing no change in the epicardium, but a significant reduction 
in the number of pHH3-positive EPDCs in mutant hearts compared to control in the myocardium (n = 6–4). 
(E,G) Periostin immunohistochemistry on X-Gal stained Crim1+/FLOX; + /WT1-CreERT2; R26R and Crim1FLOX/
FLOX; + /WT1-CreERT2; R26R sections at 17.5 dpc, counter stained with 1%DAB followed by Hematoxylin 
staining, showing (E), a periostin- and X-Gal-positive cardiac fibroblast (arrow), (F), an X-Gal-positive  
EPDC (open arrowhead) and (G) a periostin-positive cardiac fibroblast (double open arrowheads).  
(H,I) quantification of % periostin-positive cells among X-Gal-positive myocardial cells in left and right 
ventricles, showing a decrease in number of cardiac fibroblasts (n = 3–5). *P < 0.05. n.s., not significant; LV,  
left ventricle; RV, right ventricle. Scale bars (A,B) 50 μ m; (E–G) 10 μ m.
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sections were counterstained with nuclear fast red (NFR; Vector Laboratories). Others were subjected to cell 
biological and immunohistochemical analyses as detailed below.
Tamoxifen administration. Tamoxifen (MP Biomedicals, 02156738) was dissolved in corn oil at a concen-
tration of 20 mg/ml. To induce WT1-CreERT224,50, two doses of 2 mg tamoxifen52  were injected intraperitoneally 
to pregnant dams (at 9.5 dpc and 10.5 dpc), prior to harvesting the mouse embryos.
Scanning electron microscopy. 13.5 dpc embryos were collected from intercrosses of Crim1+/Δflox mice, 
and the hearts were dissected and fixed in 2.5% glutaraldehyde in PBS for 1 hour at room temperature. Samples 
were then washed 3 times with PBS and stored at 4 °C until processing for scanning electron microscopy as pre-
viously described53. Scanning electron microscopy was performed using a CM-500 Benchtop Scanning Electron 
Neoscope.
Antibodies. Primary antibodies/lectin used in the study were: rabbit polyclonal anti-phospho-Histone 
H3 (pSer10; Millipore #06-570); rabbit monoclonal anti-cleaved caspase 3 (activated caspase 3; Cell Signalling 
Technology #9664); rabbit monoclonal anti-phospho-AKT (pSer473; D9E; Cell Signalling Technology 
#4060); rabbit monoclonal anti-phospho-ERK1/2 (pThr202/pTyr204; D13.14.4E; Cell Signalling Technology 
#4370); rabbit monoclonal anti-phospho-SMAD1/5 (pSer463/pSer465; Invitrogen #700047); rabbit polyclonal 
anti-phospho-SMAD2 (pSer465/pSer467; Millipore AB3849); mouse monoclonal anti-smooth muscle α -actin 
(clone 1A4, Santa Cruz Biotechnology, sc-3225); rabbit anti-β -catenin (whole antiserum; Sigma Aldrich #C2206); 
rabbit polyclonal SM22 alpha (Abcam Ab14106); rabbit polyclonal anti-periostin (Abcam Ab92460); mouse mon-
oclonal anti-Wilms’ Tumor 1 (WT1; Dako #M3561); MF20 (supernatant, Developmental Studies Hybridoma 
Bank) and Isolectin B4 (Invitrogen). Secondary antibodies for immunofluorescence experiments were Alexa 
Fluor-488, − 594 or − 633-conjugated secondary antibodies (Invitrogen). TSA plus Cyanine 3 system was used 
for signal amplification in the case of pERK1/2 and pAKT (PerkinElmer #NEL744001KT) Secondary antibodies 
for immunohistochemistry experiments were anti-rabbit HRP (Promega; #W4011), anti-mouse HRP (Promega; 
#W4021), anti-rabbit biotin (Sigma; # B7389). The Vectastain Elite ABC kit (Standard) was also used (Vector 
Laboratories; #PK6100).
Immunohistochemistry. Experiments using mouse antibodies were blocked with mouse-on-mouse 
(Vector MOM kit; BMK 2202) blocking reagent for one hour. Sections were primed with MOM diluent for five 
minutes after washes in 1 × PBS twice. Mouse primary and secondary antibodies were diluted in MOM pro-
tein diluent. Immunohistochemistry using pHH3 was performed and sections counterstained with 1% DAB 
followed by NFR staining. Immunohistochemistry to detect periostin used anti-rabbit biotin and Vectastain 
ABC as secondary and tertiary antibodies. Vectastain ABC reagents were prepared as per manufacturer’s pro-
tocols. After one-hour incubation with anti-rabbit biotin, Vectastain ABC was added for 30 minutes in room 
temperature, followed by hematoxylin staining. Indirect immunofluorescence on tissue sections was performed 
on paraformaldehyde-fixed, paraffin-embedded samples as described6. For immunofluorescence involving detec-
tion of cleaved caspase 3 or PHH3, paraffin sections were subject to heat-induced antigen retrieval in a citrate 
buffer (pH 6.0). Immunofluorescence on cryosectioned samples was performed to detect β -Catenin, MF20, 
phospho-SMAD1/5, phospho-SMAD2, phospho-AKT and phospho-ERK1/2. Tyramide amplification according 
to manufacturer’s methods was used for signal amplification of phospho-ERK1/2 and phospho-AKT.
Primary epicardial explant cultures and migration assays. 11.5 dpc embryos were collected from 
intercrosses of Crim1+/KST264 mice, and the ventricular component was dissected from the rest of the heart in 
sterile PBS and cultured in DMEM supplemented with 10% FCS and penicillin/streptomycin in 4-well tissue 
culture plates. Once the epicardium had grown out from the primary culture, the ventricular mass was removed. 
The epicardial cells were grown to confluence and were passaged once and plated at a high confluence. After two 
days of further culture, the primary epicardial cells were used in a modified Boyden chamber assay. Epicardial 
cultures were collected after trypsin treatment to completely dissociate cells, washed and resuspended in DMEM 
(with 10% FCS). 1,000 cells in identical volumes were placed in the upper chamber of 6.5 mm transwell culture 
inserts (polycarbonate filter, 5.0 μ m pore size, Corning). After 16 hours of culture, the cells in the upper part of the 
transwell inserts were removed using a cotton swab, and the cells that had migrated through the polycarbonate 
filter were quantified after fixation in 4% PFA in PBS and staining with DAPI. Epicardial identity was confirmed 
after enrichment by immunofluorescence for the transcription factor WT-124,54, using standard techniques as 
described6.
In situ hybridization. Section in situ hybridization was performed as previously described55. Whole-mount 
in situ hybridization was performed as previously described56 with minor changes. Hybridization was performed 
with a riboprobe concentration of 0.4 μ g/mL in pre-hybridization solution. Color detection was performed with 
the chromogenic substrate NBT/BCIP (Roche). Samples were then washed, post-fixed in 4% PFA/PBS, and pho-
tographed. At least three embryos of each genotype/gene probe were analyzed. Some whole-mount samples were 
processed for paraffin infusion and sectioned as described above.
Quantitative real-time PCR analysis. Ventricular samples from Crim1+/+ and Crim1Δflox/Δflox hearts were 
microdissected, homogenized and total RNA was extracted using an RNeasy Mini Kit (Qiagen, #74104). Reverse 
transcription was performed using SuperscriptIII (Invitrogen) and qPCR was performed. Briefly, 500 ng total 
RNA was reverse-transcribed with random primers and dNTPs. cDNA was diluted 1/5 with RNase/DNase-free 
water. qPCRs were carried out in a QuantStudio6 (Applied Biosystems) using SYBR green (Takara) and standard 
www.nature.com/scientificreports/
13Scientific RepoRts | 6:19832 | DOI: 10.1038/srep19832
qPCR conditions. The data were analyzed with the QuantStudio6 software, with TFIID used as a relative standard. 
All samples were tested in triplicate. Relative transcript levels were assessed using the Δ Ct method. Statistical 
analyses were performed using a two-tailed unpaired t-test. The primer sequences used in this study were pur-
chased from Sigma-Aldrich, and are detailed below:
Periostin: Forward 5′-AAGCTGCGGCAAGACAAG-3′ 
Periostin: Reverse 5′-TCAAATCTGCAGCTTCAAGG-3′ 
Collagen1a: Forward 5′-AGACATGTTCAGCTTTGTGGAC-3′ 
Collagen1a: Reverse 5′-GCAGCTGACTTCAGGGATG-3′ 
Collagen3a: Forward 5′-ACGTAGATGAATTGGGATGCAG-3′ 
Collagen3a: Reverse 5′-GGGTTGGGGCAGTCTAGTG-3′ 
Collagen5a: Forward 5′-CTACATCCGTGCCCTGGT-3′ 
Collagen5a: Reverse 5′-CCAGCACCGTCTTCTGGTAG-3′ 
Transgelin: Forward 5′-CCTTCCAGTCCACAAACGAC-3′ 
Transgelin: Reverse 5′-CTAGGATGGACCCTTGTTGG-3′ 
Alpha smooth muscle actin: Forward 5′-ACTCTCTTCCAGCCATCTTTCA-3′ 
Alpha smooth muscle actin: Reverse 5′-ATAGGTGGTTTCGTGGATGC-3′ 
Myosin heavy chain 11: Forward 5′-ACGCCCTCAAGAGCAAACT-3′ 
Myosin heavy chain 11: Reverse 5′-CCCTTCTGGAAGGAACAATG-3′ 
Calponin1: Forward 5′-GAAGGTCAATGAGTCAACTCAGAA-3′ 
Calponin1: Reverse 5′-CCATACTTGGTAATGGCTTTGA-3′ 
Myosin heavy chain 7: Forward 5′-TGCTGAGGCCCAGAAACAAGTG-3′ 
Myosin heavy chain 7: Reverse 5′-CTGGATTTGAGTGTCCTTCAGCAG-3′ 
Nkx2-5: Forward 5′-ATTGACGTAGCCTGGTGTCTCG-3′ 
Nkx2-5: Reverse 5′-AGTGTGGAATCCGTCGAAAGTGC-3′ 
Tie2: Forward 5′-AGAGGCCGAACATTCCAAGTAGC-3′ 
Tie2: Reverse 5′-GGCCAAACAAACTGGCTTCTGC-3′ 
PDGFRα: Forward 5′-TTGCACAGCCTCTGTTTGTTGC-3′ 
PDGFRα: Reverse 5′-ATGGTGTCATGCAAGGCCCAAAG-3′ 
PDGFRβ: Forward 5′-CAGTCCCGGCTACCCTATCT-3′ 
PDGFRβ: Reverse 5′-GACCCAGAGTTTTCTCGGCA-3′ 
Tcf21: Forward 5′-CATTCACCCAGTCAACCTGA-3′ 
Tcf21: Reverse 5′-CCACTTCCTTCAGGTCATTCTC-3′ 
TFIID: Forward 5′-ACGGACAACTGCGTTGATTTT-3′ 
TFIID: Reverse 5′-ACTTAGCTGGGAAGCCCAAC-3′ 
Imaging and data analysis. Bright-field images of tissue sections were captured using an Olympus BX-51 
BF/DF slide microscope with Canon digital cameras with DP Controller software (Olympus). Whole-mount 
images were captured using either an Olympus SZX-12 stereo-microscope with DP Controller software, 
or a Zeiss Stemi 2000 stereo-microscope with an AxioCam digital camera with AxioVision software (Zeiss). 
Fluorescent images of tissue sections were captured on an Olympus IX-81 laser scanning confocal microscope 
and an Olympus FV1000 upright laser scanning confocal microscope with Olympus Fluoview software (Ver3.1a). 
Images were adjusted for colour levels, brightness and contrast, and figures compiled, using Adobe Photoshop 
software. The number of samples included in data averages is indicated in the figure legends where applicable. To 
determine the statistical significance of the prevalence of phenotypes among mutant and control groups, a Z-test 
was used (Fig. 2N). Epicardial defects examined and quantified include either a loss of squamous morphology 
or blebbing. For the analysis of 13.0 dpc compact myocardium thickness and cell density (Fig. 3), sections were 
immunolabelled for Acta2 and PECAM-1, and nuclei counter-stained with DAPI as described above. 40× fields 
of view of the ventricular compact myocardium were imaged on a laser scanning confocal microscope on each of 
three–five non-consecutive sections for each sample analyzed. The compact myocardium was considered as the 
actin-positive area of the ventricular chambers, bounded on the endocardial side by the base of the trabeculae 
(delineated by PECAM-1 staining). To determine cell density, the area was determined from confocal images 
using either Olympus Fluoview or ImageJ software, and the number of DAPI-stained nuclei quantified using 
ImageJ software. For the quantification of the pHH3-positive and CC3-positive cells at 13.0 dpc, immunolabel-
ling was performed as described above. The ventricular compact myocardium was imaged on a laser scanning 
confocal microscope (multiple images at 40× objective) on five–seven non-consecutive sections for each sample 
analyzed. Cells were scored as epicardial or sub-epicardial if they were on the periphery of the section and were 
actin-negative. Statistical significance between pooled data from mutant and control groups was determined 
using a two-tailed, unpaired Student’s t-test.
For the analysis of epicardium-derived cells using the using the WT1-CreERT2 line, 2–4 non-consecutive, 
coronal sections from each sample (X-Gal-positive; WT1-CreERT2) (Fig. 4I,M) were quantified and the average 
of X-Gal-positive cells in the mid-ventricular region per sample was measured. For analysis using the WT1-Cre 
line, 16 non-consecutive, coronal sections from each sample (X-Gal-positive; WT1-Cre) were quantified and the 
total number X-Gal-positive cells in the ventricles was counted (data not shown). Cells were scored as epicardial, 
sub-epicardial if they were on the periphery of the section, or intramyocardial. For the analysis of the location of 
epicardium-derived cells (X-Gal-positive, WT2-CreERT2/WT1-Cre; epicardial, sub-epicardial, or intramyocar-
dial), a two-way ANOVA with Bonferroni’s post-test was used.
For quantification of β -Catenin (Fig. 5Q–U), sections were co-immunolabelled for MF20 and 40× images 
were acquired using a laser scanning confocal microscope from at least 2 sections for each sample. Cells were 
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scored as epicardial or sub-epicardial if they were on the periphery of the section and were MF20-negative. 
β -Catenin accumulation at adherens junctions between epicardial cells27 was quantified, with the junctions being 
defined as points of contact between two epicardial cells. Statistical significance between pooled data from mutant 
and control groups was determined using a two-tailed, unpaired Student’s t-test.
For quantification of cardiac fibroblasts and proliferating EPDCs (Fig. 6), 20X images were acquired using a 
slide microscope from a minimum of three non-consecutive sections for each sample. The number of X-Gal- and 
periostin-positive and X-Gal- and pHH3-positive cells were counted using ImageJ software and data analyzed 
using two-tailed, unpaired Student’s t-test and two-way ANOVA respectively. Positive cells were identified as 
those that possessed both blue β -gal and a corresponding brown nucleus denoted by DAB staining.
For quantification of phospho-SMAD levels (Fig. 5A–H, Supplementary Fig. 6A,H), 40× images were acquired 
with a laser scanning confocal microscope from at least five sections for each sample and for phospho-ERK1/2 
and phospho-AKT levels (Fig. 5I–P, Supplementary Fig. 6I–P), from at least 2 sections for each sample. To deter-
mine average signal intensity/cell, unsaturated confocal images were used, and signal intensity determined using 
the Integration function in Olympus Fluoview software. The number of DAPI-stained nuclei in the demarcated 
area was quantified using ImageJ software. Average signal per cell determined was divided by 1000 for graphical 
representation. Statistical significance between pooled data from mutant and control groups was determined 
using a two-tailed, unpaired Student’s t-test. Quantified data shown are mean ± standard deviation.
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